IL292391A - Bracelets and methods for treating acromegaly - Google Patents
Bracelets and methods for treating acromegalyInfo
- Publication number
- IL292391A IL292391A IL292391A IL29239122A IL292391A IL 292391 A IL292391 A IL 292391A IL 292391 A IL292391 A IL 292391A IL 29239122 A IL29239122 A IL 29239122A IL 292391 A IL292391 A IL 292391A
- Authority
- IL
- Israel
- Prior art keywords
- sirna
- certain embodiments
- group
- alkyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925659P | 2019-10-24 | 2019-10-24 | |
| PCT/US2020/057185 WO2021081420A2 (en) | 2019-10-24 | 2020-10-23 | Conjugates and methods for treating acromegaly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292391A true IL292391A (en) | 2022-06-01 |
Family
ID=75620892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292391A IL292391A (en) | 2019-10-24 | 2020-10-23 | Bracelets and methods for treating acromegaly |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220288214A1 (https=) |
| EP (1) | EP4048801A4 (https=) |
| JP (1) | JP7668032B2 (https=) |
| CN (1) | CN114616339A (https=) |
| AU (1) | AU2020371736A1 (https=) |
| BR (1) | BR112022007725A2 (https=) |
| CA (1) | CA3158917A1 (https=) |
| IL (1) | IL292391A (https=) |
| WO (1) | WO2021081420A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020585A1 (en) * | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322651A1 (en) * | 2004-05-14 | 2011-05-18 | Rosetta Genomics Ltd | MicroRNAs and uses thereof |
| CA2917229A1 (en) * | 2013-07-02 | 2015-01-08 | Isis Pharmaceuticals, Inc. | Modulators of growth hormone receptor |
| BR112016022742B1 (pt) * | 2014-05-01 | 2022-06-14 | Ionis Pharmaceuticals, Inc | Composto químico, composição compreendendo o composto e uso dos mesmos |
| WO2015179693A1 (en) * | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| DK3607069T3 (da) | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| JP7406793B2 (ja) * | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | 2テイル自己デリバリー型siRNAおよび関連方法 |
| EP3775209A1 (en) * | 2018-04-05 | 2021-02-17 | Silence Therapeutics GmbH | Sirnas with at least two ligands at different ends |
-
2020
- 2020-10-23 CA CA3158917A patent/CA3158917A1/en active Pending
- 2020-10-23 WO PCT/US2020/057185 patent/WO2021081420A2/en not_active Ceased
- 2020-10-23 BR BR112022007725A patent/BR112022007725A2/pt unknown
- 2020-10-23 IL IL292391A patent/IL292391A/en unknown
- 2020-10-23 US US17/770,504 patent/US20220288214A1/en not_active Abandoned
- 2020-10-23 JP JP2022523585A patent/JP7668032B2/ja active Active
- 2020-10-23 AU AU2020371736A patent/AU2020371736A1/en not_active Abandoned
- 2020-10-23 CN CN202080075748.1A patent/CN114616339A/zh active Pending
- 2020-10-23 EP EP20879819.9A patent/EP4048801A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN114616339A (zh) | 2022-06-10 |
| EP4048801A4 (en) | 2023-11-22 |
| JP2022553056A (ja) | 2022-12-21 |
| WO2021081420A3 (en) | 2021-06-03 |
| JP7668032B2 (ja) | 2025-04-24 |
| EP4048801A2 (en) | 2022-08-31 |
| AU2020371736A1 (en) | 2022-06-02 |
| BR112022007725A2 (pt) | 2022-08-16 |
| US20220288214A1 (en) | 2022-09-15 |
| WO2021081420A2 (en) | 2021-04-29 |
| CA3158917A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230110295A1 (en) | Targeted compositions | |
| JP7507495B2 (ja) | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 | |
| CA3118142A1 (en) | Therapeutic methods | |
| AU2025275263A1 (en) | Targeting ligands | |
| JP2023505434A (ja) | 肝線維症を治療するためのコンジュゲート及び方法 | |
| JP7190794B2 (ja) | 核酸医薬及び多分岐脂質の複合体 | |
| US20250270555A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
| JP2022534069A (ja) | 核酸、薬物組成物及び複合体並びに調製方法と使用 | |
| JP2015523853A (ja) | Atp2a2発現を調節するための組成物及び方法 | |
| CN113613661B (zh) | 用于抑制HIF-2α(EPAS1)的表达的RNAi试剂、其组合物和使用方法 | |
| IL302530A (en) | Targeted conjugates involving modified siRNA | |
| IL292391A (en) | Bracelets and methods for treating acromegaly | |
| CA3186763A1 (en) | Conjugate of double-stranded sirna analogue | |
| WO2026000397A1 (zh) | 一种靶向sptbn1的反义寡核苷酸及其应用 | |
| NZ787057A (en) | Targeted nucleic acid conjugate compositions | |
| CN119662638A (zh) | 一种调节血管紧张素原agt表达的双链rna组合物及其应用 | |
| CN121627785A (zh) | 包含亲脂性单体的寡核苷酸以及其在非肝递送中的应用 |